B. Riley Forecasts Vaxart's FY2024 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley raised their FY2024 earnings per share estimates for shares of Vaxart in a research note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of ($0.40) per share for the year, up from their previous forecast of ($0.54). The consensus estimate for Vaxart's current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart's Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.27) EPS and FY2026 earnings at ($0.28) EPS.

Separately, Oppenheimer began coverage on Vaxart in a research note on Thursday, August 15th. They issued an "outperform" rating and a $4.00 target price for the company.

Vaxart Price Performance

NASDAQ:VXRT opened at $0.61 on Thursday. Vaxart has a 1-year low of $0.52 and a 1-year high of $1.54. The firm has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $0.77.

Institutional Trading of Vaxart

Several institutional investors have recently made changes to their positions in VXRT. Mesirow Financial Investment Management Inc. increased its stake in Vaxart by 100.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 20,000 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of Vaxart during the 1st quarter valued at $56,000. Sequoia Financial Advisors LLC purchased a new stake in Vaxart during the 2nd quarter worth $65,000. XTX Topco Ltd raised its position in Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 122,387 shares during the period. Finally, Monaco Asset Management SAM acquired a new position in shares of Vaxart during the second quarter worth about $402,000. 18.05% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.